Preexisting Immunity to Adenovirus in Rhesus Monkeys Fails To Prevent Vector-Induced Toxicity

ABSTRACT In an earlier study we evaluated innate immune responses to a first-generation adenoviral vector infused into the portal vein of rhesus monkeys who had never been exposed to adenovirus previously. In these animals, the systemic administration of E1/E3-deleted adenoviral vectors resulted in immediate activation of innate immunity and serious toxicity caused by targeting of vector to antigen-presenting cells and systemic inflammation. We analyze here how these responses are affected by vector-specific preexisting immunity that was induced by intramuscular immunization 6 months prior to evaluation. Our results show that preexposure to the vector substantially diminishes the transgene expression in most tissues but has little effect on gene transfer. Significantly, preimmunization does not eliminate systemic vector-induced toxicity. These conclusions are based on the presence of clinical features of coagulopathy and elevated levels of proinflammatory cytokine interleukin-6 in the serum of animals treated with vector after intramuscular immunization. Furthermore, preexisting immunity appears to induce a vector-specific inhibitory effect on erythroid progenitor development in the bone marrow that is not found when naive animals are challenged with vector.

[1]  Robert E. Lewis,et al.  CLUSTER OF DIFFERENTIATION (CD) ANTIGENS , 2004, Immunology Guidebook.

[2]  R. Crystal,et al.  Adenovirus Vectors for Gene Therapy , 2003 .

[3]  T. Iba,et al.  [Disseminated intravascular coagulation]. , 2003, Nihon rinsho. Japanese journal of clinical medicine.

[4]  R. M. Burnett,et al.  Replication-Defective Vector Based on a Chimpanzee Adenovirus , 2001, Journal of Virology.

[5]  James M. Wilson,et al.  “Stealth” Adenoviruses Blunt Cell-Mediated and Humoral Immune Responses against the Virus and Allow for Significant Gene Expression upon Readministration in the Lung , 2001, Journal of Virology.

[6]  J. Wilson,et al.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  J. Wilson,et al.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  O. Danos,et al.  Successful Interference with Cellular Immune Responses to Immunogenic Proteins Encoded by Recombinant Viral Vectors , 2001, Journal of Virology.

[9]  B. Trapnell,et al.  Internalization of Adenovirus by Alveolar Macrophages Initiates Early Proinflammatory Signaling during Acute Respiratory Tract Infection , 2000, Journal of Virology.

[10]  A. Bout,et al.  Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity , 2000, Gene Therapy.

[11]  N. Templeton,et al.  Gene therapy : therapeutic mechanisms and strategies , 2000 .

[12]  M. Lusky,et al.  Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. , 2000, Human gene therapy.

[13]  E. Furth,et al.  Gene transfer into the liver of nonhuman primates with E1-deleted recombinant adenoviral vectors: safety of readministration. , 1999, Human gene therapy.

[14]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[15]  J. Margolick,et al.  CD56 identifies monocytes and not natural killer cells in rhesus macaques. , 1999, Cytometry.

[16]  T. van der Poll,et al.  Disseminated Intravascular Coagulation , 1999, Thrombosis and Haemostasis.

[17]  T. Libermann,et al.  Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. , 1999, Human gene therapy.

[18]  B. Trapnell,et al.  Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses. , 1998, Human gene therapy.

[19]  H. Ertl,et al.  Cytotoxic T-Lymphocyte Target Proteins and Their Major Histocompatibility Complex Class I Restriction in Response to Adenovirus Vectors Delivered to Mouse Liver , 1998, Journal of Virology.

[20]  K. Matsushima,et al.  Inhibition of Immature Erythroid Progenitor Cell Proliferation by Macrophage Inflammatory Protein-1α by Interacting Mainly With a C-C Chemokine Receptor, CCR1 , 1997 .

[21]  J. Kolls,et al.  Liver-directed gene transfer in non-human primates. , 1997, Human gene therapy.

[22]  R. Steinman,et al.  Dendritic cells in the T‐cell areas of lymphoid organs , 1997, Immunological reviews.

[23]  J. Wilson,et al.  Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy , 1996, Journal of virology.

[24]  J. Wilson,et al.  Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. , 1996, Human molecular genetics.

[25]  M. Kay,et al.  Adenovirus-mediated hepatic gene transfer in mice: comparison of intravascular and biliary administration. , 1996, Human gene therapy.

[26]  Hanns Lochmüller,et al.  Toxicity of Replication-Defective Adenoviral Recombinants in Dissociated Cultures of Nervous Tissue , 1996, Experimental Neurology.

[27]  B. Baum,et al.  Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. , 1996, Human gene therapy.

[28]  Liangji Zhou,et al.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Boivin,et al.  Safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lungs of nonhuman primates. , 1996, Human gene therapy.

[30]  J. Gall,et al.  Circumventing the immune response to adenovirus-mediated gene therapy. , 1996, Gene therapy.

[31]  A. Pavirani,et al.  Long‐term humoral and cellular immunity induced by a single immunization with replication‐defective adenovirus recombinant vector , 1995, European journal of immunology.

[32]  Ronald G. Crystal,et al.  Transfer of Genes to Humans: Early Lessons and Obstacles to Success , 1995, Science.

[33]  Liangji Zhou,et al.  Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. , 1995, Journal of immunology.

[34]  H. Ertl,et al.  Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.

[35]  R. Crystal,et al.  Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis , 1994, Nature Genetics.

[36]  R. Crystal,et al.  Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. , 1994, Human gene therapy.

[37]  M. Kay,et al.  Assessment of recombinant adenoviral vectors for hepatic gene therapy. , 1993, Human gene therapy.

[38]  R. Steinman,et al.  The distinct surface of human blood dendritic cells, as observed after an improved isolation method. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Nemunaitis,et al.  Human marrow stromal cells: response to interleukin-6 (IL-6) and control of IL-6 expression. , 1989, Blood.

[40]  P. Lowenstein,et al.  Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  R. Crystal,et al.  Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. , 1997, Human gene therapy.

[42]  R. Crystal,et al.  Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. , 1997, Human gene therapy.